Broncho-Vaxom
Atopic Dermatitis
OM Pharma SAPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
1 Active assets in the Atopic Dermatitis cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
TACROLIMUS Astellas Pharma China, Inc. | Phase 4 | BB |
pf-04965842 Pfizer | Phase 2 | CCC |
Dupilumab Sanofi | Phase 2 | CCC |
Itepekimab Regeneron Pharmaceuticals | Phase 2 | CC |
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →